Regulation of Amyloidogenic Secretases During Apoptosis
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
April 01, 2005 - March 31, 2007
Grant ID
A2005015
Summary
Evidence is accumulating that stroke significantly increases the risk of AD representing either a precipitating or a triggering event. Extensive studies have shown that stroke or head trauma results in neuronal cell death by the activation of a cell death program termed apoptosis. Apoptosis is characterized by the activation of a family of protease called caspases. The pharmacological inhibition of caspases has been shown to reduce cell death. Dr. Tanzi’s findings indicate that treatment of stroke and head trauma with caspase inhibitors might be useful not only to prevent neuronal cell death as a consequence of the acute events, but also to prevent the increase in Aβ production that contributes to AD pathogenesis. Dr. Tanzi’s proposed experiments should not only increase our understanding of the regulation of the amyloidogenic secretases, but suggest novel therapeutic strategies for treating and preventing AD.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD